Reaction
Hypersensitivity Pneumonitis reporting signals
As of the last recalculation, Hypersensitivity Pneumonitis appears in 1,117 FAERS reports alongside 32 co-occurring drug terms. The strongest observed disproportionality signal is DAPTOMYCIN (PRR 112.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Daptomycin | 53 | 112.3 | 113.0 |
| Amikacin | 42 | 47.6 | 47.7 |
| Nintedanib | 54 | 33.7 | 33.7 |
| Adalimumab-Fkjp | 61 | 25.9 | 25.9 |
| Adalimumab-Aaty | 60 | 24.9 | 24.9 |
| Adalimumab-Adaz | 60 | 22.3 | 22.4 |
| Ciclesonide | 16 | 22.2 | 22.2 |
| Pemetrexed | 20 | 17.7 | 17.7 |
| Baricitinib | 8 | 15.6 | 15.6 |
| Pemetrexed Disodium | 30 | 15.0 | 15.1 |
| Rifampin | 11 | 14.2 | 14.2 |
| Paclitaxel (Aibumin-Bound) | 52 | 12.3 | 12.3 |
| Paclitaxel | 60 | 11.9 | 11.9 |
| Durvalumab | 12 | 11.1 | 11.1 |
| Mepolizumab | 26 | 10.0 | 10.0 |
| Pembrolizumab | 53 | 9.8 | 9.8 |
| Brentuximab Vedotin | 5 | 9.1 | 9.1 |
| Pertuzumab | 13 | 9.0 | 9.0 |
| Gemcitabine | 17 | 8.2 | 8.2 |
| Olaparib | 9 | 8.1 | 8.1 |
| Gemcitabine Hydrochloride | 22 | 7.9 | 7.9 |
| Encorafenib | 4 | 7.6 | 7.6 |
| Nivolumab | 37 | 7.3 | 7.3 |
| Ipilimumab | 16 | 7.0 | 7.0 |
| Obinutuzumab | 6 | 6.8 | 6.8 |
| Sevoflurane | 3 | 6.7 | 6.7 |
| Benralizumab | 7 | 6.6 | 6.6 |
| Docetaxel Anhydrous | 23 | 6.5 | 6.5 |
| Docetaxel | 23 | 6.5 | 6.5 |
| Pirfenidone | 12 | 5.5 | 5.5 |
| Alirocumab | 5 | 3.7 | 3.7 |
| Osimertinib | 6 | 3.5 | 3.5 |